Scorpius Holdings Gestione

Gestione criteri di controllo 4/4

Scorpius Holdings Il CEO è Jeff Wolf, nominato in Aug2008, e ha un mandato di 16.08 anni. la retribuzione annua totale è $ 575.00K, composta da 100% di stipendio e 0% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.58% delle azioni della società, per un valore di € 13.93K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5 anni e 7.7 anni.

Informazioni chiave

Jeff Wolf

Amministratore delegato

US$575.0k

Compenso totale

Percentuale dello stipendio del CEO	100.0%
Mandato del CEO	16.1yrs
Proprietà del CEO	0.6%
Durata media del management	5yrs
Durata media del Consiglio di amministrazione	7.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jeff Wolf rispetto agli utili di Scorpius Holdings?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$575k	US$575k	-US$40m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$50m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$3m	US$562k	-US$41m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$6m	US$540k	-US$35m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$6m	US$440k	-US$26m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$3m	US$428k	-US$20m
Sep 30 2019	n/a	n/a	-US$22m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$1m	US$417k	-US$16m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$12m
Dec 31 2017	US$964k	US$417k	-US$12m

Compensazione vs Mercato: La retribuzione totale di Jeff ($USD 575.00K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 474.54K ).

Compensazione vs guadagni: La retribuzione di Jeff è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jeff Wolf (61 yo)

16.1yrs

Mandato

US$575,000

Compensazione

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D. founded Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (formerly known as Heat Biologics, Inc.) in August 2008 and has been Chairman...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeffrey Wolf	Founder	16.1yrs	US$575.00k	0.58% € 13.9k
William Ostrander	CFO, Controller & Secretary	5yrs	US$375.00k	0.0010% € 24.7
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato
George Peoples	Chief Medical Advisor	7.4yrs	Nessun dato	Nessun dato
Ania Szymanska	Site Head of Quality	less than a year	Nessun dato	Nessun dato
Joe Payne	President & COO of Scorpius BioManufacturing	less than a year	Nessun dato	Nessun dato

5.0yrs

Durata media

Gestione esperta: Il team dirigenziale di 1HB0 è esperto e expertise (durata media dell'incarico 5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jeffrey Wolf	Founder	16.1yrs	US$575.00k	0.58% € 13.9k
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato
John K. Prendergast	Independent Lead Director	8.4yrs	US$301.00k	0.038% € 916.3
John Monahan	Independent Director	14.8yrs	US$81.50k	0% € 0
Llew Keltner	Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato
Anthony Tolcher	Scientific Advisory Board Member	6.5yrs	Nessun dato	Nessun dato
Roger Cohen	Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato
Richard Myers	Chairman of BioThreat Advisory Board	2.3yrs	Nessun dato	Nessun dato
Gary Acton	Member of Scientific & Clinical Advisory Board	no data	Nessun dato	Nessun dato
Robert Negrin	Member of Scientific Advisory Board	6.9yrs	Nessun dato	Nessun dato
Edward Smith	Independent Director	13.8yrs	US$92.50k	0% € 0
Robert Levy	Member of Scientific Advisory Board	6.9yrs	Nessun dato	Nessun dato

7.7yrs

Durata media

70yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 1HB0 sono considerati esperti (durata media dell'incarico 7.7 anni).

Scorpius Holdings Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Recent updates

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

NYSE American Withdraws Delisting Determination of Scorpius Holdings Common Stock

Scorpius Holdings Set to Launch First Mammalian Cgmp Campaign At San Antonio Facility in the 2024 3Rd Quarter

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.

Scorpius Holdings, Inc Successfully Executes First cGMP Microbial Batches at San Antonio Facility

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

New minor risk - Shareholder dilution

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold €169k worth of stock

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

New 90-day high: €11.05

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

New 90-day low: €0.79

New 90-day low: €0.81

Third quarter 2020 earnings released: US$0.062 loss per share

Revenue beats expectations

Revenue beats expectations

Third quarter 2020 earnings released: US$0.062 loss per share

Jeff T. Hutchins Leave as A Chief Scientific and Operating Officer from Heat Biologics, Inc

Earnings released

Heat Biologics Regains Compliance with Nasdaq Minimum Bid Price Rule

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Membri del Consiglio di amministrazione

Durata media

Età media